MedTrace Logo

Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage

NCT02139618 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-03-06

No results posted yet for this study

Summary

Treatment of actinic damage has included multiple procedures but to date there is limited scientific evidence to support the preferential use of one of these therapies according to their efficacy, safety and pain tolerance by patients. This study aims to assess the efficacy of methyl aminolevulinate + daylight vs placebo + daylight to treat facial photodamage

Conditions

  • Facial Photodamage

Interventions

DRUG

Methyl Aminolevulinate (MAL)

DRUG

Placebo

Sponsors & Collaborators

  • Grupo de Investigacion Dermatologica (GRID)

    collaborator UNKNOWN

  • IPS Universitaria-Universidad de Antioquia

    collaborator UNKNOWN

  • Fundación Dermabase

    lead OTHER

Principal Investigators

  • Gloria Sanclemente, Dr · Universidad de Antioquia. Medellin, Colombia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02139618 on ClinicalTrials.gov